Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 may affect male fertility but is not sexually transmitted: a systematic review

Ilan Tur-Kaspa, M.D.,a Tomer Tur-Kaspa,a,b Grace Hildebrand, B.A.,a and David Cohen, M.D.a

a Institute for Human Reproduction (IHR), Chicago and Oak Brook, Illinois, and Valparaiso, Indiana, and b Wesleyan University, Middletown, Connecticut

Objective: To determine if SARS-CoV-2, which has led to the rapidly spreading COVID-19 global pandemic, is sexually transmitted. Since the putative receptor for the virus is identified in reproductive organs, it is also important to examine if COVID-19 may affect human fertility.

Evidence Review: A systematic review of English publications was conducted up to December 11, 2020 in PubMed, NIH iCite COVID-19 portfolio, Cochrane Library, and Google Scholar databases, searching for SARS-CoV-2 in the testes; seminal, prostatic, and vaginal fluids; and cervical smears. A total of 1,997 records were identified, duplicates were removed, and 1,490 records were reviewed for eligibility by examining titles and abstracts. Subsequently, 202 full-text relevant articles were reviewed by 2 independent reviewers. Forty-seven studies (literature reviews, editorials, and guidelines) were assessed qualitatively, and 23 studies that tested the male and female reproductive tracts of patients with COVID-19 for SARS-CoV-2 were quantitatively analyzed.

Results: No epidemiological investigations to date have described evidence suggesting that COVID-19 is an STD. While angiotensin-converting enzyme 2 receptor is found in the reproductive organs, the lack of co-expression of the TMPRSS2 modulatory protein, required for SARS-CoV-2 cell entry, in testicular cells, sperm, or oocytes, argues against the hypothesis that gametes transmit SARS-CoV-2. Molecular detection studies of SARS-CoV-2 RNA in the male and female reproductive tracts were summarized: 98.0% (293/299) of the seminal fluids, 16/17 testicular biopsies, all 89 prostatic fluids, 98.3% (57/58) of the vaginal fluids, all 35 cervical smears, and all 16 oocyte samples tested negative for SARS-CoV-2. None of the studies confirmed sexual transmission of SARS-CoV-2. Nonetheless, COVID-19 may have detrimental effects on male reproduction by inducing orchitis and/or decreasing testosterone levels, sperm counts, and motility.

Conclusion: On the basis of the current worldwide published information, COVID-19 is not an STD. This information is important for clinicians, proposed guidelines for public health, U.S. Food and Drug Administration guidelines for gamete and tissue donor eligibility, and fertility treatments. Universal precautions, currently practiced worldwide, are adequate and sufficient at this time to prevent the transmission of known or unknown viral infections. We suggest that recovered patients of COVID-19, especially those with infertility, should be evaluated for their ovarian and testicular function. (Fertil Steril Rev® 2021;2:140–9. ©2021 by American Society for Reproductive Medicine.)

Key Words: COVID-19, infertility, IVF, SARS-CoV-2, sexual transmission

Discuss: You can discuss this article with its authors and other readers at https://www.fertstertdialog.com/posts/xfnr-d-20-00033
• No epidemiological investigations to date have suggested that COVID-19 is an STD. The lack of co-expression of viral angiotensin-converting enzyme 2 receptors and the TMPRSS2 modulatory protein in testicular cells, sperm, and oocytes further rejects the hypothesis that gametes transmit SARS-CoV-2.

• This systematic review of available global clinical data up to December 11, 2020 regarding SARS-CoV-2 in the testes; seminal, prostatic, and vaginal fluids; cervical smears; and oocytes concludes that the virus is not sexually transmitted. This information is important for public health guidelines, U.S. Food and Drug Administration guidelines on gamete donor eligibility, and fertility treatments.

• COVID-19 may affect male fertility. Further prospective and longitudinal controlled studies are needed to investigate the potential effects of COVID-19 on human fertility.

SARS-CoV-2 has led to a large-scale global pandemic of COVID-19. As of December 11, 2020, it has infected more than 71 million people worldwide and caused over 1.5 million deaths globally, with over 15 million infected and almost 300,000 deaths in the United States alone. Coronavirus infections are endemic in humans and responsible for 15%–30% of respiratory tract infections yearly. The SARS outbreak in 2002–2003 infected approximately 8,000 people worldwide, with a 9% mortality rate (1). The 2012 Middle East respiratory syndrome coronavirus outbreak infected only approximately 2,500 people but had a 35% mortality rate (2). COVID-19 clinical manifestations have been summarized by others (3–6).

While no previous coronavirus infection was reported to be a sexually transmitted disease (STD) (1, 2, 7, 8), a May 2020 scientific publication (9) reported the finding of SARS-CoV-2 RNA in the semen of 6 out of 38 patients with COVID-19, heightening concern for its potential sexual transmission (9). Furthermore, since the putative angiotensin-converting enzyme 2 (ACE2) receptor for SARS-CoV-2 was found in reproductive organs (7, 10–14), it was important to examine if the virus targets and infects the human reproductive tract and affects fertility and to resolve if it is sexually transmitted or not. It is clear that COVID-19 can be transmitted with intimate sexual contact through droplets and fomites, but from a clinical and public health perspective, it is imperative to determine if sexual transmission occurs as well.

To determine if COVID-19 is an STD or not and clarify its possible effect on fertility, we conducted a systematic review of global epidemiological investigations, molecular receptor identification, and detection studies of SARS-CoV-2 in the male and female reproductive tracts.

MATERIALS AND METHODS
A systematic review of the literature was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (15) on English literature available through PubMed, NIH iCite COVID-19 portfolio, Cochrane Library, and Google Scholar databases. Briefly, the search terms included the following: SARS-CoV-2 and/or COVID-19 with STD, STD, sperm, seminal fluid, semen fluid, semen, prostatic fluid, orchitis, testes, oocyte, ovary, vaginal fluid, cervical smear, follicular fluid, embryo, and implantation. The exact search terms are listed in the online supplement (Supplemental Table 1, available online). While the initial literature search ended on July 15, 2020, following the special pandemic circumstances and the Editorial request, the search was extended to December 11, 2020. This updated comprehensive search found no data that changed any of the conclusions.

Sexual transmission of SARS-CoV-2 was considered if it occurred through vaginal intercourse, vaginal penetration, or insemination. Other forms of possible viral transmission or shedding, such as by blood, oral-fecal, and urine, have been discussed by others (16–23). No study documenting the transmission of SARS-CoV-2 through homosexual sexual relationships was found in our search. Articles were included if original data on SARS-CoV-2 RNA in the male or female reproductive tracts were presented, if there was a discussion of such possible sexual transmission, or if commentary regarding any COVID-19 effect on human reproduction was included.

The quality of the included studies was rated according to the Oxford Centre for Evidence-Based Medicine levels of evidence by 2 investigators independently, with discrepancies resolved after joint article review and discussion (24).

RESULTS
The search produced a total of 1,997 records. After duplicates were removed, 1,490 records were screened and assessed for eligibility by examining titles and abstracts (by investigators T.T. and G.H.). Next, 202 full-text relevant articles were reviewed and evaluated by 2 independent reviewers (I.T. and D.C.) for inclusion in the study. After applying inclusion and exclusion criteria, 47 qualitative studies (literature reviews, editorials, and guidelines) remained, and 23 quantitative studies that tested the male and female reproductive tracts of 404 adult patients with COVID-19 for SARS-CoV-2 RNA were selected for inclusion.

The results of the literature search are detailed in the online supplement with a PRISMA-style flow diagram (Supplemental Fig. 1, available online). In total, 70 reports formed the basis of this review.

Evidence from epidemiological investigations
For a viral infection to be labeled as an STD, virus infectivity via sexual intercourse or insemination and not just the presence of its viral particles is required (25). Classifying a viral infection as an STD requires observational epidemiological studies. The transmission of SARS-CoV-2 through respiratory droplets and aerosol has been documented, but no epidemiological investigation to date has implicated, or even suspected, sexual transmission (16, 26–31).
Evidence for SARS-CoV-2 targeting the human reproductive tract

Evidence for ACE2/TMPRSS2-mediated mechanism for SARS-CoV-2 cell entry. SARS-CoV-2 uses the ACE2 receptor and cellular protease TMPRSS2 to enter the target cells. Both are essential for viral spread and disease in the infected host (32). Expression of the ACE2 receptor is identified in the ovary, vagina, uterus, and placenta of women (10, 14) and testis of men (7, 11–13). ACE2 receptor identification in the reproductive tracts led to speculation that SARS-CoV-2 might infect the gonads, be found in seminal and/or vaginal fluid, or attach to sperm and/or oocytes. Furthermore, the evidence of SARS-CoV-2-mediated orchitis suggested that testicular infection might damage the testis-blood barrier and permit viral shedding into semen.

It is important to distinguish, however, between the localization of receptors, localized inflammation (orchitis), and virus infectivity. Although SARS-CoV also uses ACE2 receptors, no SARS virus was detected in the testes or vaginal fluids in pathologic specimens during the SARS epidemic in 2002–2003, even in men with pathologically documented inflammatory orchitis (8).

Because TMPRSS2 is highly expressed in the prostate, Song et al. (33) investigated TMPRSS2 and ACE2 co-expression in human prostate epithelial cells. They analyzed 24,519 epithelial cells from a normal human prostate data set using publicly available single-cell RNA sequencing data. While 18.65% of these cells expressed TMPRSS2, only 0.32% of all epithelial cells (78 of 24,519) expressed ACE2. Overall, the co-expression of ACE2 and TMPRSS2 in the prostatic cell types investigated was approximately 0.4%–0.6% (33). No SARS-CoV-2 was found in the prostatic fluid of 98 men with COVID-19 in 3 different studies, supporting the aforementioned finding of a very low co-expression of ACE2 and TMPRSS2 in the prostate (34–36).

Recently, it was reported that while the ACE2 receptor is found in reproductive organs, TMPRSS2 is not co-expressed in testicular cells, sperm, or cumulus-enclosed oocytes (may be expressed at <0.01% of the cells) (13, 32, 37). Since TMPRSS2 is required for SARS-CoV-2 cell entry, this finding suggests that SARS-CoV-2 is unlikely to enter testicular cells through an ACE2/TMPRSS2-mediated mechanism (13, 32, 37).

Furthermore, 16 oocytes from 2 asymptomatic SARS-CoV-2-positive egg donors were all negative for the viral RNA (38), and while in 5 of 16 oocytes ACE2 was detectable, TMPRSS2 was undetectable in all oocytes. Since both ACE2 and TMPRSS2 are essential for viral spread (32), these data oppose the proposition that sperm and oocytes might be infected by SARS-CoV-2 and argue that the virus is not sexually transmitted (13, 37, 39).

Evidence for SARS-CoV-2 in the male reproductive tract. Tables 1 and 2 depict published global studies investigating the presence of SARS-CoV-2 RNA in the male reproductive tract. Table 1 summarizes findings in the seminal fluid (9, 36, 37, 40–50), and Table 2 summarizes findings in the testes and prostatic fluid (34–36, 40, 51, 52).

Of all seminal fluids tested, 98.0% (293/299) were negative for the virus (Table 1) (9, 36, 37, 40–50). Most of these men demonstrated mild COVID-19 symptoms (163/299), and negative results of nucleic acid testing were documented as early as 4 days after confirmed COVID-19 diagnosis. Not surprisingly, the majority of viral testing was performed in patients during disease recovery. One study, of the 14 reviewed, identified 6 men with positive seminal fluid viral RNA tests (2.0% of all the men from all 14 studies) (9). Of these 6 men, 4 were in the acute stage of infection and 2 were in recovery, between 6 and 16 days after COVID-19 diagnosis. The investigators of this outlier study (9) provided limited information on the reverse transcription polymerase chain reaction test kit they used, the test kit’s limits of detection, gene targets, and cycle threshold and did not describe the semen collection protocol (9, 53). Since this positive report (9) demonstrated only molecular detection and not viral shedding, we and others (37, 40–44) agree with the investigator’s (9) own assessment that their results should be confirmed by others before it influences groups formulating guidelines or clinical practice. Furthermore, in 2 other studies where testing was also obtained within the acute stage of infection, the seminal fluids of all 14 men tested negative for SARS-CoV-2 (43, 44). Interestingly, 7 men who demonstrated orchitis-like symptoms, identified in 2 of the studies, also all tested negative for SARS-CoV-2 in their seminal fluid (37, 43).

Finally, all 89 prostatic fluids tested were negative for the virus (Table 2) (34–36). One of the 17 testicular biopsies (40, 51) tested positive for SARS-CoV-2 RNA, but the investigators (51) of that study questioned their own finding, commenting that “the reverse transcription polymerase chain reaction likely detected the virus present in the blood rather than in testicular tissue” (51).

Taken together, these data suggest that SARS-CoV-2 is not sexually transmitted through sperm or semen (34–37, 40–50, 54).

Evidence for SARS-CoV-2 in the female reproductive tract. Table 3 presents the currently published investigations of SARS-CoV-2 RNA in the vaginal fluid, cervical smears, and human oocytes. Specifically, 98.3% (57/58) of the vaginal fluids tested negative (14, 55–57), and all 35 cervical smears tested negative for SARS-CoV-2 as well (56). Vaginal fluid testing was performed as early as 8 days after diagnosis, and most of the women (44/58) demonstrated severe COVID-19 symptoms (14, 55–57). In one study (56), while all 35 vaginal fluids tested negative, the infection rate of the patients’ sexual partner was 42.9%. Interestingly, 2 women with negative vaginal fluid tests engaged in sexual activity with their partners 14 days before the onset of symptoms and continued until the day samples were collected. One of the partners tested positive for COVID-19, and the other did not (56). Only 1 woman (14) tested positive for SARS-CoV-2 RNA in the vaginal fluid out of 58 women tested in 4 studies (1.7%) (14, 55–57). This woman was 67-years-old and initially had 2 negative vaginal samples after COVID-19 diagnosis (14). After these initial negative tests, she tested positive on 2 occasions and subsequently tested negative again. There was no information about the test kit used in this case report (14).
| Studies          | City, country       | Study type (quality rating) | Date of publication | No. of men | Mean age (range) | Mean days from diagnosis (range) | Severity of COVID-19 | Seminal fluid result | Control | Reverse transcription polymerase chain reaction manufacturer |
|------------------|---------------------|-----------------------------|---------------------|------------|------------------|-------------------------------|----------------------|----------------------|----------|-------------------------------------------------------------|
| Song et al. (40) | Nanjing, China      | Cohort (4)                  | 4/16/2020           | 12         | 30 (22–38)       | 29 (14–42)                    | Asymptomatic (1/12), mild (11/12) | All negative          | No       | Huirui Biotechnology                                          |
| Ning et al. (41) | Wuhan, China        | Cohort (4)                  | 4/16/2020 (Preprint) | 17         | 35 (23–46)       | 27 (12–64)                    | Asymptomatic (8/17), mild (9/17) | All negative          | No       | Sansure Biotech                                              |
| Pan et al. (37)  | Wuhan, China        | Cross-sectional (4)         | 4/17/2020           | 34         | 39 (18–55)       | 31 (8–75)                     | Mild (34/34)                                      | All negative<sup>a</sup> Negative<sup>b</sup> | No       | Anda Gene Ltd altona Diagnostics                             |
| Li et al. (9)    | Shangqiu, China     | Cohort (4)                  | 5/7/2020            | 38         | ≥ 15 (NA)        | 11 (6–16)                     | NA                             | 84.2% negative (32/38)<sup>c</sup> | No       | NA                                                           |
| Holtmann et al. (43) | Düsseldorf, Germany | Cohort control (3b)        | 5/29/2020          | 18         | 42 (32–52)       | 31 (26–34)                    | Mild (14/18), moderate (4/18)<sup>d</sup> | All negative          | N = 14 | PE Applied Biosystems                                            |
| Guo et al. (44)  | Shandong, China     | Case Series (4)             | 6/29/2020          | 23         | 41 (20–62)       | 12 (6–17)                     | Mild (18/23), moderate (5/23) | All negative<sup>e</sup> | No       | Huirui Biotechnology                                          |
| Ma et al. (45)   | Wuhan, China        | Cross-sectional (4)         | 7/4/2020           | 12         | 31.5 (25–46)     | 78.5 (56–109)                 | Mild (1/12), moderate (11/12) | All negative          | No       | NA                                                           |
| Rawlings et al. (46) | San Diego, USA     | Cross-sectional (4)         | 8/7/2020           | 6          | 38 (28–45)       | 12 (6–17)                     | Asymptomatic (1/9), mild (9/9) | All negative          | No       | ddPCR                                                        |
| Pavone et al. (47) | Palermo, Italy     | Cross-sectional (4)         | 8/14/2020          | 9          | 41 (28–52)       | 42 (7–88)                     | Mild (6/6)                                      | All negative          | No       | NA                                                           |
| Kayaaslan et al. (48) | Ankara, Turkey     | Cross-sectional (4)         | 9/1/2020           | 16         | 33.5 (18–54)     | 1 (0–7)                       | Mild (16/16)                                  | All negative          | N = 22 | Bio-Speedy                                                   |
| Li et al. (49)   | Wuhan, China        | Cross-sectional            | 10/23/2020        | 23         | 41 (27–55)       | 26 (4–42)                     | Mild (14/23), moderate (9/23) | All negative          | No       | NA                                                           |
| Ruan et al. (36) | Wuhan, China        | Cross-sectional (4)         | 11/4/2020          | 70         | 31 (27–36)       | 80 (64–93)                    | Mild (15%), moderate (42%), severe (43%) | All negative          | No       | DAAN Gene                                                    |
| Terniz et al. (50) | Istanbul, Turkey    | Cross-sectional (4)         | 11/26/2020        | 20         | 37.5 (18–60)     | (1–5)                         | Asymptomatic (10/299), mild (163/299), moderate (58/299), severe (30/299, NA (38/299) | 98.0% negative (293/299), 2.0% positive (6/299) | N = 10 | Coyote Bioscience Co.                                      |
| Total            | 10 cities, 5 countries — | April to November 2020 | 299             | 36 (15–62) | 31 (0–109)       | 12 (10–197)                   | Asymptomatic (10/299), mild (163/299), moderate (58/299), severe (30/299, NA (38/299) | 98.0% negative (293/299), 2.0% positive (6/299) | —       | —                                                            |

Note: NA = not available or not reported.
<sup>a</sup> Six men had orchitis during the time of infection and all tested negative (37).
<sup>b</sup> Urine was collected and tested on the same day as the seminal fluid and also tested negative (42).
<sup>c</sup> Of the 6 positive patients, 4 were at the acute stage of infection, and 2 were in recovery (9).
<sup>d</sup> Subjects with a moderate infection demonstrated impaired sperm quality (43).
<sup>e</sup> The sperm counts, motility, and morphology of the patients were within the normal range (44).

Tur-Kaspa. COVID-19 affects fertility, not an STD. Fertil Steril Rev 2021.
| Sample tested | Studies | City, country | Study type (quality rating) | Date of publication | No. of men | Mean age (range) | Mean days from diagnosis (range) | Severity of COVID-19 | Control | Reverse transcription polymerase chain reaction manufacturer |
|---------------|---------|---------------|----------------------------|---------------------|------------|-----------------|---------------------------------|---------------------|---------|------------------------------------------------------------|
| Testes        | Song et al. (40) | Nanjing, China | Cohort (4)                 | 4/16/2020           | 1          | 67 (42–87)      | 42 (23–75)                      | Deceased (1/1)       | No      | Huirui Biotechnology                                      |
|               | Yang et al. (51) | Wuhan, China   | Case series (4)            | 5/26/2020           | 10         | 65 (42–87)      | 42 (23–75)                      | Deceased (10/10)      | No      | Lifesver Biotechnology                                    |
|               | Achua et al. (52) | New York City, USA | Case series (4)            | 11/30/2020          | 6          | 49.5 (22–83)    | 15 (7–27)                       | Deceased (6/6)        | No      | NA                                                        |
| Total         | 3 cities, 2 countries | —             | April to November 2020     | 17                 | 60.5 (22–87) | 33 (7–75)       |                                | Deceased (17/17)      | No      | —                                                         |
| Prostatic fluid | Quan et al. (34) | Shenzhen, China | Cohort (4)                 | 3/30/2020 (preprint)| 18         | 60 (20–60+)     | NA (3–14+)                      | Mild (18/18)          | N = 5   | BGI                                                       |
|               | Zhang et al. (35) | Wuhan, China   | Case series (4)            | 6/10/2020           | 10         | 57 (29–76)      | 11 (8–17)                       | Mild (10/10)          | No      | NA                                                        |
|               | Ruan et al. (36) | Wuhan, China   | Cross-sectional (4)        | 11/4/2020           | 61         | 31 (27–36)      | 80                              | Mild (15%), moderate (42%), severe (43%) | No      | DAAN Gene                                                 |
| Total         | 2 cities, 1 country | —             | March to November 2020     | 89                 | 49 (20–76) | 45.5 (3–17)     |                                | Mild (37/89), moderate (26/89), severe (26/89) | Negative (5/5) | —                                                         |

Note: NA = not available or not reported.

* For the one positive testicular biopsy for SARS-CoV-2, the investigators concluded “it is likely that reverse transcription polymerase chain reaction detected the virus present in blood rather than in testicular tissue” (51).

** Electron microscopy of testicular tissue for 3 of the reverse transcription polymerase chain reaction-negative patients failed to identify viral particles (51).

Tur-Kaspa. COVID-19 affects fertility, not an STD. Fertil Steril Rev 2021.
Two studies investigated semen samples in patients recovering from COVID-19.

TABLE 3

| Studies | City | Study type | Country | Data of COVID-19 diagnosis | No. of women | Mean age (range) | No. of pregnant women (range) | Severity of COVID-19 | Reverse transcription fluid result (quality rating) | Reverse transcription cervical smear result (quality rating) | Reverse transcription oocyte result (quality rating) | Oocyte analysis | Comments |
|---------|-----|------------|---------|---------------------------|-------------|-----------------|-----------------------------|---------------------|-----------------------------------------------|---------------------------------------------------|----------------|----------|---------|
| Qiu et al. (55) | Wuhan, China | Cohort | Cohort | 4/2/2020 | 4 | 66 (52–80) | 28 (17–40) | Severe (10/10) | All negative | NA | NA | No | NA | NA | No | NA | NA | NA | NA |
| Scorzolini et al. (14) | Rome, Italy | Case report | Case report | 4/16/2020 | 1 | 65 | NA | NA | Initially negative/then positive/then negative | C | 1/58 | 1.7% positive | 1/58 | 1 | C | 1/58 | 1.7% positive | 1/58 | 1 | C | 1/58 | 1.7% positive | 1/58 |
| Cui et al. (56) | Wuhan, China | Cohort | Cohort | 5/3/2020 | 3 | 62 (37–81) | 34 (24–74) | Severe (35/35) | All negative | DAAN Gene and BioPerfectus Technologies | No | NA | No | NA | NA | No | NA | NA | No | NA | No | NA | NA | No |
| Aslan et al. (57) | Sakarya, Turkey | Cross-sectional | Cross-sectional | 7/5/2020 | 12 | 32 (24–40) | NA | NA | Mild (12/12) | All negative | NA | NA | No | NA | NA | No | NA | NA | No | NA | No | NA | NA | No |

Note: *Not available or not reported.*

a Twenty-seven patients were diagnosed with COVID-19 on the basis of a positive SARS-CoV-2 throat swab. The other 8 patients were diagnosed on the basis of clinical symptoms (56).
b All 12 women were pregnant with an average pregnancy of 26.0 ± 1.3 weeks gestation (57).

Evidence for the impact of COVID-19 on fertility:

- Viral-induced testicular damage may cause hypogonadism, reduced spermatogenesis, and increased testicular inflammation and reduced spermatogenesis. Biopsies demonstrated a decreased sperm count and motility compared with that in women and their role in the disease (5).
- Increased testicular inflammation or infection increased with the severity of COVID-19 (40, 51) revealed only testicular inflammation and reduced spermatogenesis in patients with acute orchitis, epididymitis, or both; an abscess; scrotal wall edema; thickening; enlargement and heterogeneous echogenicity of the testis-blood barrier might potentially lead to indirect damage to newborns during vaginal delivery. Sixteen oocytes from 2 asymptomatic SARS-CoV-2-infected women were retrieved from 2 amniotic SARS-CoV-2-infected women by in vitro fertilization cycle supports the conclusion that oocytes obtained from asymptomatic women by in vitro fertilization do not transmit SARS-CoV-2, supporting the notion that the virus is not transmitted vertically from mother to fetus (57). Supporting this notion is the finding that in 91 hospitalized patients with COVID-19, the virus was not detected in the semen of men using bedside ultrasound examination of the scrotum in 14 men with a contraindication of the injection in children (19).

The possibility of SARS-CoV-2 remaining in the reproductive tract of women and their role in the disease is discussed by others (3, 4, 60).

Viral-induced testicular damage may cause hypogonadism, reduced spermatogenesis, and increased testicular inflammation, reduced spermatogenesis, and increased testicular inflammation or infection during COVID-19. The observed differences in the results of imaging and histological examination (35, 36) are presumed to result from the inflammatory damage or infection during COVID-19 revealed 11% patients with related testicular infection. A survey of 91 hospitalized patients with acute scrotal inflammation and reduced spermatogenesis revealed a decreased sperm count and motility compared with women in the age of the majority of men seen for infertility, the risk of the age of the majority of men for infertility, the risk of fertility affecting the prevalence of acute orchitis, epididymitis, or both; an abscess; scrotal wall edema; thickening; enlargement and heterogeneous echogenicity of the testis-blood barrier might potentially lead to indirect damage to newborns during vaginal delivery. Sixteen oocytes from 2 asymptomatic SARS-CoV-2-infected women were retrieved from 2 amniotic SARS-CoV-2-infected women by in vitro fertilization cycle supports the conclusion that oocytes obtained from asymptomatic women by in vitro fertilization do not transmit SARS-CoV-2, supporting the notion that the virus is not transmitted vertically from mother to fetus (57). Supporting this notion is the finding that in 91 hospitalized patients with COVID-19, the virus was not detected in the semen of men using bedside ultrasound examination of the scrotum in 14 men with a contraindication of the injection in children (19).

The possibility of SARS-CoV-2 remaining in the reproductive tract of women and their role in the disease is discussed by others (3, 4, 60).

Viral-induced testicular damage may cause hypogonadism, reduced spermatogenesis, and increased testicular inflammation, reduced spermatogenesis, and increased testicular inflammation or infection during COVID-19. The observed differences in the results of imaging and histological examination (35, 36) are presumed to result from the inflammatory damage or infection during COVID-19 revealed 11% patients with related testicular infection. A survey of 91 hospitalized patients with acute scrotal inflammation and reduced spermatogenesis revealed a decreased sperm count and motility compared with women in the age of the majority of men seen for infertility, the risk of fertility affecting the prevalence of acute orchitis, epididymitis, or both; an abscess; scrotal wall edema; thickening; enlargement and heterogeneous echogenicity of the testis-blood barrier might potentially lead to indirect damage to newborns during vaginal delivery. Sixteen oocytes from 2 asymptomatic SARS-CoV-2-infected women were retrieved from 2 amniotic SARS-CoV-2-infected women by in vitro fertilization cycle supports the conclusion that oocytes obtained from asymptomatic women by in vitro fertilization do not transmit SARS-CoV-2, supporting the notion that the virus is not transmitted vertically from mother to fetus (57). Supporting this notion is the finding that in 91 hospitalized patients with COVID-19, the virus was not detected in the semen of men using bedside ultrasound examination of the scrotum in 14 men with a contraindication of the injection in children (19).

The possibility of SARS-CoV-2 remaining in the reproductive tract of women and their role in the disease is discussed by others (3, 4, 60).
motility, and morphology to be within normal ranges (44). Since elevated body temperature has a known deleterious effect on sperm count and motility, the fever, and not the SARS-CoV-2 infection per se, might have caused the reduction in total motile sperm counts observed in some patients (39).

Thus, unless the patient has active COVID-19 and contamination from blood, urine, or feces should be avoided, in vitro fertilization treatment and embryo and gamete cryopreservation seem to pose no significant risk to the embryos produced.

In summary, COVID-19 may cause inflammation in approximately 5%–10% of men of reproductive age and, rarely, even infection of the testes. Such orchitis is highly correlated with the severity of the disease and age. Sperm and oocytes are unlikely to be susceptible to infection by SARS-CoV-2, and there is no evidence to support that COVID-19 is an STD (63).

To date, the possible effects of COVID-19 on the ovary or residual ovarian reserve have not been investigated (64). We suggest that the survivors of COVID-19, especially those suffering from infertility, should be evaluated for their short- and long-term ovarian and testicular function (54, 60, 63, 65).

**DISCUSSION**

The number of infected patients and information about the clinical course of COVID-19 is increasing rapidly (3, 4). Clinicians worldwide should continue to follow national and professional guidelines and the Centers for Disease Control and Prevention, U.S. Food and Drug Administration (FDA), and World Health Organization websites to stay updated.

To determine if SARS-CoV-2 is sexually transmitted and if guidelines should be specifically updated to address this concern, this systematic review summarizes recent global data of epidemiological investigations, molecular receptor identification, and detection studies of SARS-CoV-2 RNA in the male (in testicular biopsies, seminal, and prostatic fluids) and female (in vaginal fluids, cervical smears, and oocytes) reproductive tracts. The available evidence provides no suggestion that sperm, semen, or the female genital tract transmits SARS-CoV-2 (34–37, 40–50, 55–57). A recent review of the 21st century viral pandemics (66) concurs that current evidence (9, 37, 40–42) does not support that SARS-CoV-2 is present in the semen and is therefore unlikely to be sexually transmitted. Any form of sexual intimacy worsens the risks of COVID-19 transmission (67–69), and while SARS-CoV-2 can be transmitted during sexual contact by aerosols and fomites, on the basis of currently available information, it is concluded that the virus is not sexually transmitted. There is the potential for transmission of SARS-CoV-2 via blood (16), urine (17–19), and feces or oral-fecal (20–23), and these forms of transmission have been discussed by others (16–23). Homosexual sexual practices have not been reported to transmit the virus.

The identification of viral receptors in human reproductive organs raised concerns about the vulnerability of infected gametes transmitting the virus sexually by artificial insemination or during vaginal births from mothers to newborns. While the ACE2 receptor has been identified in reproductive organs, its co-expression with TMPRSS2, required for SARS-CoV-2 cell entry, is lacking in testicular and prostatic cells, sperm, or oocytes. This suggests that the hypothesis that sperm and oocytes may become infected by SARS-CoV-2 should be rejected; these cell types are also unlikely vectors to sexually transmit or infect an embryo (13, 37, 39). Lastly, to date, there is no evidence of vertical transmission of COVID-19 during labor (acquisition during passage through the vaginal canal) (58, 59, 66). Therefore, proposing that SARS-CoV-2 infection of reproductive tract tissues via ACE2 receptors leads to sexual or vertical transmission (10, 14) is a premature theory and is not supported by current scientific evidence.

Nonetheless, COVID-19 may have temporary or permanent detrimental effects on male reproduction. It may involve endocrine alterations in luteinizing hormone and testosterone (17) and decreased sperm parameters (43) or may induce an inflammatory orchitis resulting in fibrosis and further loss of testicular function (37, 43, 51). It is not known if, or how, it might also affect female fertility, ovarian endocrine function, or ovarian reserve. Prospective and longitudinal control studies are warranted to elucidate any possible long-term consequences of SARS-CoV-2 on human fertility.

There are several limitations for the studies reviewed. Because of the exponential rate of viral infections and the variations in international and local characteristics and responses, there remain multiple areas of testing data acquisition and interpretation uncertainty. This has led to difficulties in creating best practice protocols to prevent further spread of SARS-CoV-2. The urgency to develop testing quickly resulted in less rigorous approval processes of SARS-CoV-2 reverse transcription polymerase chain reaction test kits, varying test kit sensitivities and specificities, and diminished methodological standards for conducting studies. With a rush to publish data and supply frontline providers with data, studies are performed in locations with differing prevalence of patient infectivity using different sampling methods and a lack of controls (65). These problems synergize and make data interpretation and, more importantly, data comparisons difficult.

A major limitation of the studies that specifically tested the male and female reproductive tracts of patients with COVID-19 for SARS-CoV-2 is that, overall, the published evidence is generally considered low quality, with ratings ranging from 3b to 5 (Tables 1–3). In addition, the consequences of some study design irregularities are evident in investigations demonstrating the presence of viral RNA particles but not a contiguous virus in tissues and bodily fluids. Nonetheless, the studies included in this review consist of all of the currently published international data through December 11, 2020 and include preprints as well to maximize the inclusion of available data.

There is only 1 publication (out of 14) that describes SARS-CoV-2 RNA in the semen of 6 men (9), and in only 1 case report was SARS-CoV-2 RNA found in vaginal fluid (14). Both studies with positive results failed to provide information on the specifics of the test kits employed and neither had a control group for comparison. Moreover, the infectivity of the viral particles detected is unknown. Although all
investigations consisted of a small number of variables, they represent different populations with variable disease severity and, taken together, suggest that SARS-CoV-2 is not found in the male and female reproductive tracts.

While guidelines for the prevention of SARS-CoV-2 transmission have been published by the Centers for Disease Control and Prevention and World Health Organization [67, 68], to establish best practice guidelines, more comprehensive published evidence and systematic reviews are needed. Professional societies for infertility and reproductive medicine, including the American Society for Reproductive Medicine, European Society of Human Reproduction and Embryology, and International Federation of Fertility Societies, published a joint statement significantly revising initial recommendations regarding fertility treatments during the COVID-19 pandemic [7, 54, 70]. To respond to the rapidity of COVID-19 spread worldwide, all of these societies produced interim guidelines without the usual rigorous protocol review. Now, this review provides such societies the evidence-based data needed to refine their guidelines.

To address the questions of gamete donor eligibility during this pandemic, the FDA has determined that since “respiratory viruses, in general, are not known to be transmitted by implantation, transplantation, infusion, or transfer of human cells, tissues, or cellular or tissue-based products” and “there have been no reported cases of transmission of COVID-19 via human cells, tissues, or cellular or tissue-based products,” the current guidelines remain unchanged [28]. Additionally, at this time, the FDA does not even recommend screening blood donor candidates for SARS-CoV-2 [28]. Individuals in the acute phase of the disease may benefit from specific precautions to avoid sexual intercourse for 2–4 weeks, but the universal precautions already practiced worldwide to prevent the transmission of all infectious diseases are likely adequate and sufficient to prevent viral transmission. This systematic review is in concordance with these guidelines and concludes that COVID-19 is not an STD.

CONCLUSION

On the basis of the current international scientific data, and unless new conclusive data will be published, it is concluded that COVID-19 may affect male fertility but it is not an STD. This information is important for clinicians, guidelines for public health recommendations, FDA guidelines for gamete and tissue donor eligibility, and fertility treatments. Universal precautions practiced in clinical settings and laboratories to prevent the transmission of known or unknown viral infections are adequate and sufficient at this time. We suggest that the recovered patients of COVID-19, especially those with infertility, should be evaluated and followed-up for their ovarian and testicular function.

REFERENCES

1. World Health Organization, Department of Communicable Disease Surveillance and Response. Consensus document on the epidemiology of severe acute respiratory syndrome (SARS). Available at: https://www.who.int/csr/sarsWHOconsensus.pdf?ua=1. Accessed December 11, 2020.

2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV). Available at: https://www.who.int/en/news-room/fact-sheets/detail/middle-east-respiratory-syndrome-coronavirus-(mers-cov). Accessed December 11, 2020.

3. Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. J Am Med Assoc 2020;324:782–93.

4. Gupta A, Madhavan MV, Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. Nat Med 2020;26:1017–32.

5. Gandhi RT, Lynch JB, Del Rio C. Mild or moderate COVID-19. N Engl J Med 2020;383:1757–66.

6. Berlin DA, Gullick RM, Martinez FJ. Severe COVID-19. N Engl J Med 2020;383:2451–60.

7. Segars J, Katler Q, McQueen DB, Kotlyar A, Glenn T, Knight Z, et al. Prior and novel coronaviruses, coronavirus disease 2019 (COVID-19), and human reproduction: what is known? Fertil Steril 2020;113:1140–9.

8. X J, Qi L, Chi X, Yang J, Wei X, Gong E, et al. Orchitis: a complication of severe acute respiratory syndrome (SARS). Biol Reprod 2006;74:410–6.

9. Li D, Jin M, Bao P, Zhao W, Zhang S. Clinical characteristics and results of semen tests among men with coronavirus disease 2019. J Am Med Assoc Netw Open 2020;3:e208292.

10. Jing Y, Run-Qian L, Hao-Ran W, Hao-Ran C, Ya-Bin L, Yang G, et al. Potential influence of COVID-19/AE2 on the female reproductive system. Mol Hum Reprod 2020;26:367–73.

11. Wang Z, Xu X. scRNA-seq profiling of human testes reveals the presence of the ACE2 receptor, a target for SARS-CoV-2 infection in spermatogonia, Leydig and Sertoli cells. Cells 2020;9:920.

12. Fu J, Zhou B, Zhang L, Baiji KS, Wei C, Liu X, et al. Expressions and significances of the angiotensin-converting enzyme 2 gene, the receptor of SARS-CoV-2 for COVID-19. Mol Biol Rep 2020;47:4383–92.

13. Stanley KE, Thomas E, Leaver M, Wells D. Coronavirus disease-19 and fertility: viral host entry protein expression in male and female reproductive tissues. Fertil Steril 2020;114:33–43.

14. Scorzolini L, Corpolongo A, Castilli C, Lalle E, Mariano A, Nicastri E. Comment on the potential risks of sexual and vertical transmission of COVID-19. Clin Infect Dis 2020;71:2298.

15. Moher D, Liberati A, Tetzlaff J, Altman D, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. J Clin Epidemiol 2009;62:1006–12.

16. Wang W, Xu Y, Gao R, Lu R, Han K, Wu G, et al. Detection of SARS-CoV-2 in different types of clinical specimens. J Am Med Assoc 2020;323:1843–4.

17. Wang S, Zhou X, Zhang T, Wang Z. The need for urogenital tract monitoring of COVID-19. Nat Rev Urol 2020;17:314–5.

18. Chan VW, Chiu PK, Yee CH, Yuan Y, Ng CF, Teoh JY. A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions. World J Urol 2020;1–12.

19. Kash AH, de la Rosette J, Amini E, Abdi H, Fallah-karkar M, Vaesjelali M, et al. Urinary viral shedding of COVID-19 and its clinical associations: a systematic review and meta-analysis of observational studies. Urol J 2020;17:433–41.

20. Patri A, Gallo L, Guarino M, Fabbrocini G. Sexual transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): a new possible route of infection? J Am Acad Dermatol 2020;82:e227.

21. Amirian ES. Potential fecal transmission of SARS-CoV-2: current evidence and implications for public health. Int J Infect Dis 2020;95:363–70.

22. Cipriano M, Giacalone A, Ruberti E. Sexual behaviors during COVID-19: the potential risk of transmission. Arch Sex Behav 2020;49:1431–2.

23. Hindson J. COVID-19: faecal-oral transmission? Nat Rev Gastroenterol Hepatol 2020;17:259.

24. Oxford Centre for Evidence-Based Medicine—levels of evidence (March 2009). Available at: https://www.cebm.net/2009/06/oxford-centre-evidence-based-medicine-levels-evidence-march-2009v. Accessed December 11, 2020.

25. Feldmann H. Virus in semen and the risk of sexual transmission. N Engl J Med 2018;378:1440–1.

VOL. 2 NO. 2 / APRIL 2021
26. Stokes EK, Zambrano LD, Anderson KN, Marder EP, Raz KM, Felix SEB, et al. Coronavirus disease 2019 case surveillance - United States, January 22-May 30, 2020. MMWR Mortal Morb Wkly Rep 2020;69:759–65.

27. Ghinai I, McPherson TD, Hunter JC, Kinking HL, Christiansen D, Joshi K, et al. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet 2020;395:1137–40.

28. U.S. Food & Drug Administration. COVID-19 frequently asked questions. Available at: https://www.fda.gov/emergency-preparedness-and-respon se/coronavirus-disease-2019-covid-19/covid-19-frequently-asked-questions. Accessed December 11, 2020.

29. Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: radiologic and clinical overview. Clin Imaging 2020;66:35–41.

30. Findings from investigation and analysis of re-positive cases [press release]. KCDCDC2020. Available at: https://www.cdc.go.kr/board/board.es?mid=a30 4020000000006&biso=0. Accessed December 11, 2020.

31. Zhang W, Du RH, Li B, Zheng XS, Yang XL, Hu B, et al. Molecular and serological investigation of 2019-nCoV infected patients: implication of multiple shedding routes. Emerg Microbes Infect 2020;9:386–9.

32. Hoffmann M, Kleinert H, Schroeder S, Kröger N, Herrler T, Erichsen S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020;181:271–80.e8.

33. Song H, Sediqghiazadeh B, Cooperberg MR, Huang FW. Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells. Eur Urol 2020;78:296–8.

34. Quan W, Chen J, Liu Z, Tian J, Chen X, Wu T, et al. No SARS-CoV-2 in expressed prostatic secretion of patients with coronavirus disease 2019: a descriptive multicentre study in china. medRxiv, 2020. https://doi.org/10.1101/2020.03.26.20044198.

35. Zhang S, Wang X, Zhang H, Xu A, Fei G, Jiang X, et al. The absence of coronavirus in expressed prostatic secretion in COVID-19 patients in Wuhan city. Reprod Toxicol 2020;96:90–4.

36. Ruan Y, Hu B, Liu Z, Liu K, Jiang H, Li H, et al. No detection of SARS-CoV-2 from urine, expressed prostatic secretions, and semen in 74 recovered COVID-19 male patients: a prospective and urogynological evaluation. Androl ogy 2021;9:99–106.

37. Pan F, Xiao X, Guo J, Song Y, Li H, Patel DP, et al. No evidence of severe acute respiratory syndrome-coronavirus 2 in semen of males recovering from coronavirus disease 2019. Fertil Steril 2020;113:1135–9.

38. Barragan M, Guillén JJ, Martin-Palomino N, Rodriguez A, Vassena R. Undetectable viral RNA in oocytes from SARS-CoV-2 positive women. Hum Reprod 2021;36:390–4.

39. Eisenberg ML. Coronavirus disease 2019 and men’s reproductive health. Fertil Steril 2020;113:1154.

40. Song C, Wang Y, Li W, Hu B, Chen G, Xia P, et al. Absence of 2019 novel coronavirus in semen and testes of COVID-19 patients. Biol Reprod 2020;103:4–6.

41. Ning J, Li W, Ruan Y, Xia Y, Wu X, Hu K, et al. Effects of 2019 novel coronavirus on male reproductive system: a retrospective study. 2020. https://doi. org/10.20944/preprints202004.0280.v1. Preprint.

42. Paoli D, Pallotti F, Colangelo S, Basilio F, Mazzotti L, Turriozzi 0, et al. Study of SARS-CoV-2 in semen and urine samples of a volunteer with positive nasopharyngeal swab. J Endocrinol Invest 2020;43:1819–22.

43. Holtmann N, Edimirs P, Andree M, Doehmen C, Baston-Buest D, Adams O, et al. Assessment of SARS-CoV-2 in human semen—a cohort study. Fertil Steril 2020;114:233–8.

44. Guo L, Zhao S, Li W, Wang Y, Li L, Jiang S, et al. Absence of SARS-CoV-2 in semen of a COVID-19 patient cohort. Andrology 2021;9:42–7.

45. Ma L, Xie W, Li D, Shi L, Ye G, Mao Y, et al. Evaluation of sex-related hormones and semen characteristics in reproductive-aged male COVID-19 patients. J Med Virol 2020; https://doi.org/10.1002/jmv.26259.

46. Rawlings SA, Ignacio C, Porrachia M, Du P, Smith DM, Chailan N. No evidence of SARS-CoV-2 seminal shedding despite SARS-CoV-2 persistence in the upper respiratory tract. Open Forum Infect Dis 2020;7:ofaa325.

47. Pavone C, Gianmancio GM, Baiamonte D, Pinelli M, Bonura C, Montalbano M, et al. Italian males recovering from mild COVID-19 show no evidence of SARS-CoV-2 in semen despite prolonged nasopharyngeal swab positivity. Int J Impot Res 2020;32:560–2.

48. Kayaaslan B, Korukluoglu G, Hasanoglu I, Kalem AK, Eser F, Akinci E, et al. Investigation of SARS-CoV-2 in semen of patients in the acute stage of COVID-19 infection. Urol Int 2020;104:678–83.

49. Li H, Xiao X, Zhang J, Zafar MF, Wu C, Long Y, et al. Impaired spermatogenesis in 2019 patients. EclinicalMedicine 2020;28:100604.

50. Temiz MZ, Dincer MM, Hacibey I, Yazar RO, Celik C, Kucuk SH, et al. Investigation of SARS-CoV-2 in semen samples and the effects of COVID-19 on male sexual health by using semen analysis and serum male hormone profile: a cross-sectional, pilot study. Andrologia 2020.e13912.

51. Yang M, Chen S, Huang B, Zhong JM, Su H, Chen YJ, et al. Pathological findings in the testes of COVID-19 patients: clinical implications. Eur Urol Focus 2020;6:1124–9.

52. Achua JK, Chu KY, Ibrahim E, Khodamoradi K, Delma KS, Iakymenko OA, et al. Histopathology and ultrastructural findings of fatal COVID-19 infections on tests. World J Mens Health 2021;39:65–74.

53. Paoli D, Pallotti F, Turriozzi 0, Mazzotti L, Antonelli G, Lenzi A, et al. SARS-CoV-2 presence in seminal fluid: myth or reality. Andrology 2021;9:23–6.

54. Corona G, Baldi E, Isidori AM, Paoli D, Pallotti F, De Santos L, et al. SARS-CoV-2 infection, male fertility and sperm cryopreservation: a position statement of the Italian Society of Andrology and Sexual Medicine (SIAMS) (Società Italiana di Andrologia e Medicina della Sexualità). J Androol Invest 2020;43:113–7.

55. Quan L, Liu X, Xiao M, Xie J, Cao W, Liu Z, et al. SARS-CoV-2 is not detectable in the vaginal fluid of women with severe COVID-19 infection. Clin Infect Dis 2020;71:813–7.

56. Cui P, Chen Z, Wang T, Dai J, Zhang J, Ding T, et al. Severe acute respiratory syndrome coronavirus 2 detection in the female lower genital tract. Am J Obstet Gynecol 2020;223:131–4.

57. Aslan MM, Uluysu H, Köse Ö, Toptan H, Akdemir N, Kıroğlu M, et al. SARS-CoV-2 is not present in the vaginal fluid of pregnant women with COVID-19. J Matern Fetal Neonatal Med 2020;1–3.

58. American College of Obstetricians and Gynecologists. COVID-19 FAQs for obstetricians-gynecologists, obstetrics. Available at: https://www.acog.org/clinical-information/physician-faq/covid-19-faqs-for-ob-gyns-obstetrics. Accessed December 11, 2020.

59. Xu G, Yang Y, Du Y, Peng F, Hu P, Wang R, et al. Clinical pathway for early diagnosis of COVID-19: updates from experience to evidence-based practice. Clin Rev Allergy Immunol 2020;59:89–100.

60. Battha O, Al-Deeb T, Al-Zoubi E, Alsharou E. Impact of COVID-19 and other viruses on reproductive health. Andrologia 2020;52:e13791.

61. Ediz C, Tavukcu HH, Akan S, Kızılkan YE, Alcin A, Oz K, et al. Is there any association of COVID-19 with testicular pain and epididymo-orchitis? Int J Clin Pract 2020.e13753.

62. Chen L, Huang X, Yi Z, Deng Q, Jiang N, Feng C, et al. Ultrasound imaging findings of acute testicular infection in patients with coronavirus disease 2019: a single-center-based study in Wuhan, China. J Ultrasound Med 2020;71:813–7.

63. World Health Organization. Coronavirus disease (COVID-19) advice for the public. Available at: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public. Accessed December 11, 2020.
69. Turban JL, Keuroghlian AS, Mayer KH. Sexual health in the SARS-CoV-2 era. Ann Intern Med 2020;173:387–9.

70. American Society for Reproductive Medicine. International Federation of Fertility Services, European Society of Human Reproduction and Embryology. COVID-19 and human reproduction joint statement: ASRM/ESHRE/IFFS [press release]. Available at: https://www.asrm.org/globalassets/asrm/asrm-content/news-and-publications/covid-19/covidtaskforceupdate6.pdf.